144 related articles for article (PubMed ID: 37640994)
21. Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study.
Huang TQ; Wang R; Fang JG; He SZ; Zhong Q; Hou LZ; Ma HZ; Chen XH; Chen XJ; Li PD; Feng L; Shi Q; Lian M
World J Surg Oncol; 2020 Dec; 18(1):330. PubMed ID: 33308220
[TBL] [Abstract][Full Text] [Related]
22. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of the clinical efficacy of definitive chemoradiotherapy for patients with hypopharyngeal cancer.
Takehana K; Kodaira T; Tachibana H; Kimura K; Shimizu A; Makita C; Tomita N; Nishikawa D; Suzuki H; Hirakawa H; Hanai N; Hasegawa Y
Jpn J Clin Oncol; 2016 Apr; 46(4):344-9. PubMed ID: 26826721
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
[TBL] [Abstract][Full Text] [Related]
25. Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study.
Jin T; Liu NF; Jin QF; Hua YH; Chen XZ
Radiat Oncol; 2022 Nov; 17(1):176. PubMed ID: 36345003
[TBL] [Abstract][Full Text] [Related]
26. Patients with locally advanced hypopharyngeal carcinoma. Results over a 30-year period.
León X; López M; García J; Rovira C; Casasayas M; Quer M
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(6):315-326. PubMed ID: 30527320
[TBL] [Abstract][Full Text] [Related]
27. Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience.
Akbaba S; Held T; Lang K; Hoerner-Rieber J; Zaoui K; Forster T; Rieken S; Plinkert P; Debus J; Adeberg S
Radiat Oncol; 2019 Feb; 14(1):34. PubMed ID: 30782197
[TBL] [Abstract][Full Text] [Related]
28. Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.
Tian X; Xuan Y; Wu R; Gao S
Cancer Manag Res; 2020; 12():3323-3329. PubMed ID: 32494195
[TBL] [Abstract][Full Text] [Related]
29. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.
Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC
Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706
[No Abstract] [Full Text] [Related]
30. A 10-Year Study on Larynx Preservation Compared With Surgical Resection in Patients With Locally Advanced Laryngeal and Hypopharyngeal Cancers.
Su X; He HC; Ye ZL; Zhou DL; Liu Q; Yang XH; Long YK; Tang T; Ma JJ; Xu BH; Chen WC; He CY; Yang AK
Front Oncol; 2020; 10():535893. PubMed ID: 33178574
[TBL] [Abstract][Full Text] [Related]
31. The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: a case series.
Sittitrai P; Reunmarkkaew D; Chaiyasate S
J Otolaryngol Head Neck Surg; 2018 Oct; 47(1):62. PubMed ID: 30326958
[TBL] [Abstract][Full Text] [Related]
32. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X
Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552
[TBL] [Abstract][Full Text] [Related]
33. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
34. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Ghi MG; Paccagnella A; Ferrari D; Foa P; Alterio D; Codecà C; Nolè F; Verri E; Orecchia R; Morelli F; Parisi S; Mastromauro C; Mione CA; Rossetto C; Polsinelli M; Koussis H; Loreggian L; Bonetti A; Campostrini F; Azzarello G; D'Ambrosio C; Bertoni F; Casanova C; Emiliani E; Guaraldi M; Bunkheila F; Bidoli P; Niespolo RM; Gava A; Massa E; Frattegiani A; Valduga F; Pieri G; Cipani T; Da Corte D; Chiappa F; Rulli E;
Ann Oncol; 2017 Sep; 28(9):2206-2212. PubMed ID: 28911070
[TBL] [Abstract][Full Text] [Related]
35. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.
Fang L; Shi L; Wang W; Hu T; Rao X
Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731
[TBL] [Abstract][Full Text] [Related]
36. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
37. Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?
Sobrevilla-Moreno N; Altamirano-Garcia JI; Granados-Garcia M; Garcilazo-Reyes A; Herrera-Martinez M; Alvarez-Avitia MA
Oncology (Williston Park); 2020 Jun; 34(6):211-215. PubMed ID: 32609868
[TBL] [Abstract][Full Text] [Related]
38. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer.
Zelefsky MJ; Kraus DH; Pfister DG; Raben A; Shah JP; Strong EW; Spiro RH; Bosl GJ; Harrison LB
Head Neck; 1996; 18(5):405-11. PubMed ID: 8864731
[TBL] [Abstract][Full Text] [Related]
39. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
40. Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer.
Su CW; Lee JC; Chang YF; Su NW; Lee PH; Dai KY; Tai HC; Leu YS; Chen YJ
Tumori; 2022 Oct; 108(5):450-460. PubMed ID: 34423708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
